Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E37.46 EPS (ttm)3.44 Insider Own1.20% Shs Outstand78.69M Perf Week4.86%
Market Cap10.14B Forward P/E33.50 EPS next Y3.85 Insider Trans-23.91% Shs Float77.49M Perf Month-2.75%
Income287.00M PEG- EPS next Q0.38 Inst Own98.90% Short Float5.79% Perf Quarter13.84%
Sales752.50M P/S13.48 EPS this Y670.20% Inst Trans3.35% Short Ratio4.53 Perf Half Y18.14%
Book/sh6.02 P/B21.41 EPS next Y41.69% ROA39.10% Target Price136.67 Perf Year86.52%
Cash/sh7.23 P/C17.83 EPS next 5Y- ROE87.40% 52W Range68.31 - 141.58 Perf YTD29.37%
Dividend- P/FCF36.14 EPS past 5Y42.20% ROI44.40% 52W High-8.98% Beta1.11
Dividend %- Quick Ratio7.00 Sales past 5Y59.30% Gross Margin- 52W Low88.65% ATR4.15
Employees485 Current Ratio7.00 Sales Q/Q48.20% Oper. Margin38.70% RSI (14)54.76 Volatility3.24% 3.64%
OptionableYes Debt/Eq0.48 EPS Q/Q77.80% Profit Margin38.10% Rel Volume1.22 Prev Close131.32
ShortableYes LT Debt/Eq0.48 EarningsMay 07 AMC Payout0.00% Avg Volume990.37K Price128.87
Recom1.90 SMA203.19% SMA500.37% SMA20018.37% Volume1,207,994 Change-1.87%
May-08-15Reiterated UBS Buy $130 → $142
May-08-15Reiterated Maxim Group Buy $126 → $155
Apr-20-15Downgrade Credit Suisse Outperform → Neutral
Apr-08-15Reiterated Canaccord Genuity Buy $132 → $180
Mar-30-15Reiterated Maxim Group Buy $126 → $163
Mar-27-15Reiterated Barclays Overweight $133 → $150
Mar-25-15Reiterated Brean Capital Buy $125 → $142
Mar-02-15Reiterated Maxim Group Buy $118 → $126
Feb-26-15Reiterated Brean Capital Buy $118 → $125
Jan-29-15Reiterated Stifel Buy $112 → $128
Jan-23-15Initiated RBC Capital Mkts Sector Perform $100
Dec-15-14Reiterated UBS Buy $110 → $125
Sep-18-14Upgrade Canaccord Genuity Hold → Buy $60 → $132
Sep-12-14Reiterated Chardan Capital Markets Buy $100 → $122
Sep-11-14Reiterated Stifel Buy $89 → $112
Aug-08-14Reiterated UBS Buy $85 → $90
Aug-08-14Reiterated Stifel Buy $83 → $89
Aug-08-14Reiterated Brean Capital Buy $100 → $105
May-22-14Initiated Stifel Buy $81
Apr-16-14Initiated Canaccord Genuity Hold $60
May-21-15 02:43PM  Polaris: Our formula works
May-17-15 12:48PM  Medivation and Astellas Announce New Enzalutamide Data Presented at the 2015 American Urology Association Annual Meeting Marketwired
12:48PM  Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire
May-14-15 07:00AM  New Enzalutamide Data in Triple-Negative Breast Cancer to Be Presented at the 2015 ASCO Annual Meeting Marketwired
07:00AM  Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting PR Newswire
May-13-15 01:04PM  MEDIVATION, INC. Financials
May-09-15 08:09PM  10-Q for Medivation, Inc. at Company Spotlight
May-08-15 03:00PM  Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
09:20AM  4 Pharmaceutical Companies Leading the Breast Cancer Fight at 24/7 Wall St.
07:45AM  Medivation (MDVN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
May-07-15 06:43PM  Medivation, Jazz Q1 Reports Miss; Regeneron Beats at Investor's Business Daily
05:28PM  Medivation reports 1Q loss
05:08PM  Medivation Reports First Quarter 2015 Financial Results at noodls
04:15PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Medivation Reports First Quarter 2015 Financial Results Marketwired
07:07AM  Q1 2015 Medivation Inc Earnings Release - After Market Close
May-05-15 07:20AM  New Enzalutamide Data to Be Presented in Late Breaking Plenary Session at AUA Annual Meeting at noodls
07:00AM  New Enzalutamide Data to Be Presented in Late Breaking Plenary Session at AUA Annual Meeting Marketwired
07:00AM  Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire
12:19AM  Medivation Announces Participation at Upcoming Investor Conference at noodls
May-04-15 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
Apr-28-15 07:32AM  3 Biotech Stocks With Rising Short Interest
Apr-23-15 05:00PM  Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 at noodls
04:10PM  Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 Marketwired
Apr-20-15 07:10AM  Credit Suisse: Medivation 'Headwinds Loom'
06:35AM  Medivation downgraded by Credit Suisse
Apr-14-15 11:41AM  Two Biotech Buyout Candidates at Barrons.com
Apr-06-15 04:26PM  Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Apr-03-15 11:35AM  Xtandi Beats Casodex, Set to Top Zytiga at Barrons.com
Apr-02-15 10:32AM  Medivation's Xtandi Beats Casodex In Cancer Trial at Investor's Business Daily
07:00AM  Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial PR Newswire
07:00AM  Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial Marketwired
Mar-31-15 10:54AM  Biotech: Why It's Not a Bubble at Barrons.com
Mar-26-15 03:35PM  3 Biotech Stocks Bucking Short Interest Trends
03:20PM  Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Mar-25-15 10:36AM  Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream
Mar-24-15 07:37PM  ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOCIATION OF UROLOGY CONGRESS (pdf 110 KB) at noodls
07:09AM  Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress at noodls
07:00AM  Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress Marketwired
07:00AM  Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress PR Newswire
Mar-19-15 06:00PM  Qorvo, Allegiant Among Few Top Stocks In Buy Range at Investor's Business Daily
Mar-18-15 09:30AM  Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases
Mar-16-15 04:32PM  New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress at noodls
04:10PM  New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress PR Newswire
04:10PM  New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress Marketwired
Mar-11-15 08:22AM  Wedbush Securities Reiterates Outperform, Raises PT On Medivation On Increased International Estimates
Mar-10-15 05:51PM  New High Analysis: 2 Orphan Drugmakers Stay Strong at Investor's Business Daily
Mar-05-15 04:02PM  Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst +5.02%
Mar-03-15 11:44PM  Johnson & Johnson's Zytiga May Get a Boost at Barrons.com
Feb-27-15 07:08PM  10-K for Medivation, Inc. Company Spotlight
05:44PM  Four Hot Stocks You'll Want To Keep On Your Radar at Investor's Business Daily
09:31AM  Medivation (MDVN) Shares March Higher, Can It Continue? - Tale of the Tape
06:47AM  Can anything slow Medivation?
Feb-26-15 03:45PM  Growth-stock breakouts mean opportunity for speculators at MarketWatch +5.18%
12:12PM  Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners at Investor's Business Daily
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
Feb-25-15 07:15PM  Medivation beats Street 4Q forecasts AP
04:30PM  Medivation Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:24PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update Marketwired
02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
07:07AM  Q4 2014 Medivation Inc Earnings Release - After Market Close CCBN
Feb-24-15 07:00PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
Feb-23-15 03:05PM  Stocks Show Small Losses; Merger Talk Lifts Discovery at Investor's Business Daily
01:18PM  Stocks Quietly Lower; Domino's, Medivation Break Out at Investor's Business Daily
11:17AM  Biotech on the rise; Analyst likes Gilead CNBC
Feb-13-15 04:20PM  MEDIVATION, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Change in Directors or Prin EDGAR Online
Feb-11-15 04:10PM  Medivation Announces Fourth Quarter and Year-End 2014 Financial Results Teleconference on February 25, 2015 Marketwired
Feb-04-15 12:45PM  4 picks for shelter from the volatility CNBC
Feb-02-15 06:06AM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
Jan-30-15 11:39AM  Valeant Agrees To Buy Dendreon's Provenge at Investor's Business Daily
Jan-26-15 05:22PM  Medivation CEO's Planned Sale Hits $10.8M in Stock at Barrons.com
Jan-23-15 04:20PM  Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Zacks
Jan-22-15 07:00AM  Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer Marketwired
Jan-20-15 11:20AM  J&J Earnings Beat But Sales, Guidance Miss at Investor's Business Daily
Jan-06-15 10:05AM  UPDATE: Barclays Capital Initiates Coverage On Medivation On Multiple Upside Drivers Benzinga
Dec-29-14 07:18AM  Bullish on biotech CNBC
07:16AM  Top three pharma predictions for 2015 CNBC
Dec-22-14 04:10PM  Medivation Exercises License Option for Pidilizumab Marketwired -5.08%
Dec-18-14 08:20AM  Meet This Years Top Health Care ETF ETF Trends
Dec-12-14 06:00PM  Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer Marketwired
Dec-10-14 04:10PM  Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP Marketwired
Dec-09-14 05:26PM  MEDIVATION, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; EDGAR Online
Dec-01-14 01:00AM  US Federal Reserve will hike rates in June: Pro CNBC
Nov-28-14 05:20PM  Newly Profitable Medivation Riding High On Drug Sales at Investor's Business Daily
Nov-25-14 04:10PM  Joseph Lobacki to Become Medivation's Chief Commercial Officer Marketwired
Nov-17-14 04:10PM  Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Marketwired
Nov-14-14 02:30PM  Street Talk: HOG, LULU, BMRN, MDVN & TRS CNBC
Nov-10-14 10:38AM  Dendreon files bankruptcy protection CNBC
Nov-08-14 07:07PM  10-Q for Medivation, Inc. Company Spotlight
Nov-07-14 04:28PM  Another lackluster session for major equities Yahoo Finance Blogs +7.45%
03:30PM  Major Upgrades And Downgrades In Friday's Market Action Benzinga
12:53PM  Clarification: Earns-Medivation story AP
12:35PM  Midday movers: Allergan, Freshpet, Transocean & more at CNBC
11:15AM  Medivation Hits High After Q3 Earnings Beat at Investor's Business Daily
11:08AM  Medivation Q3 Earnings, Revenues Lag Estimates Zacks
Nov-06-14 04:18PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Third Quarter Financial Results and Provides Corporate Update Marketwired
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company's prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bierly RickChief Financial OfficerMay 20Sale130.001,000130,00014,841May 20 06:40 PM
Bierly RickChief Financial OfficerMay 08Sale125.0038548,12515,841May 12 08:07 PM
Bierly RickChief Financial OfficerMay 05Sale125.001,615201,87516,226May 06 07:42 PM
Bierly RickChief Financial OfficerMay 04Sale124.702,170270,60417,841May 06 07:42 PM
Bierly RickChief Financial OfficerApr 15Option Exercise58.103,000174,30023,011Apr 16 05:31 PM
Bierly RickChief Financial OfficerApr 15Sale132.203,000396,60020,011Apr 16 05:31 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 16Sale130.921,390181,97911,090Mar 17 05:37 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Option Exercise47.482,00094,96014,480Mar 02 09:16 PM
Svoronos DawnDirectorMar 02Sale119.753,350401,16313,639Mar 04 09:22 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Sale122.002,000244,00012,480Mar 02 09:16 PM
Hung DavidPresident and CEOMar 02Sale120.83100,89112,190,609760,977Mar 02 09:15 PM
FALBERG KATHRYN EDirectorFeb 27Buy117.6725,0002,941,68425,000Mar 02 09:13 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Option Exercise47.482,00094,96014,480Feb 27 04:56 PM
Hung DavidPresident and CEOFeb 26Sale120.1219,1092,295,373861,868Feb 27 04:55 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Sale119.293,089368,50211,391Feb 27 04:56 PM
Machado Clarence PatrickDirectorFeb 10Option Exercise9.3936,000337,86067,500Feb 12 04:21 PM
Machado Clarence PatrickDirectorFeb 10Sale103.8936,0003,739,98431,500Feb 12 04:21 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 04Sale100.8561061,5198,980Feb 06 07:03 PM
Hung DavidPresident and CEOFeb 04Sale100.483,190320,519861,868Feb 06 07:04 PM
Machado Clarence PatrickDirectorJan 27Option Exercise9.6336,000346,61367,500Jan 29 05:34 PM
Machado Clarence PatrickDirectorJan 27Sale105.3236,0003,791,39231,500Jan 29 05:34 PM
Hung DavidPresident and CEOJan 20Sale108.14100,00010,814,242865,058Jan 22 06:33 PM
Seely LynnChief Medical OfficerDec 19Option Exercise10.1831,340318,94991,194Dec 22 07:42 PM
Rhodes Jennifer JGC & Corporate SecretaryDec 03Sale113.00910102,8309,590Dec 04 04:54 PM
Machado Clarence PatrickDirectorDec 03Sale113.001,580178,54031,500Dec 04 04:53 PM
Hung DavidPresident and CEODec 03Sale113.005,420612,460965,058Dec 04 04:52 PM
Seely LynnChief Medical OfficerOct 22Option Exercise10.595,00052,92564,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 22Sale99.035,000495,14259,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 16Option Exercise10.595,00052,92564,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 16Sale93.975,000469,85059,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Option Exercise8.0024,346194,73784,200Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Sale89.1124,3462,169,36359,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerSep 18Option Exercise10.5925,000264,62584,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 18Sale99.8125,0002,495,15859,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Option Exercise8.4630,000253,80089,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Sale97.3630,0002,920,72759,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerAug 27Option Exercise10.5914,300151,36673,322Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 27Sale89.6114,3001,281,42359,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Option Exercise10.595,70060,33564,722Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Sale88.955,700507,03259,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 13Option Exercise8.3920,000167,82579,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 13Sale83.6220,0001,672,45659,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 12Option Exercise9.3912,500117,31371,522Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 12Sale84.0112,5001,050,12559,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Option Exercise9.3913,000122,00572,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Sale82.0613,0001,066,82159,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerJul 22Option Exercise6.747,50050,51366,522Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 22Sale73.967,500554,71059,022Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 02Option Exercise9.3912,000112,62071,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJul 02Sale79.0212,000948,19459,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJun 18Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 18Sale75.007,500562,53059,022Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Sale74.507,500558,76059,022Jun 19 04:35 PM